

Adenovirus E1A fragments for use in anti-cancer therapies

Published date: Aug. 28, 2012

Technology description

Category:

Therapeutic

Summary:

Up-regulation of the HER2/neu proto-oncogene occurs in several types of human cancer, including breast, ovary and prostate. HER2 up-regulation in breast cancer is predictive of aggressive disease with a poor prognosis. In addition, several studies have shown that elevated HER2 levels decrease the susceptibility of cancer cells to chemotherapy drugs. Further, treatment with siRNAs that inhibit HER2 translation was found to promote growth arrest and apoptosis of breast cancer cell lines. This invention relates to cancer therapies utilizing a fragment of adenovirus E1A that represses oncogenic genes, such as HER2/neu.

Institution

Saint Louis University

Inventors

Paul Loewenstein

Assistant Research Professor Molecular Virology <u>Maurice Green</u>

Professor and Director

Molecular Viology

联系我们



叶先生

电话: 021-65679356 手机: 13414935137

邮箱: yeyingsheng@zf-ym.com